Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2006-12-13 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appoints Dutch Distributor for Aridol 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 14 December 2006 from Pharmaxis announcing the appointment of a Dutch distributor for their product Aridol. It discusses marketing and distribution plans, product details, and forward-looking statements. There is no financial data, no regulatory filing references, no meeting materials, no voting results, no audit or management reports, and no mention of capital or financing activities. The document is a corporate announcement about a commercial partnership and product distribution, typical of a press release or general regulatory announcement. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. Given the nature of the content and the absence of financial or regulatory filing details, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements and press releases that do not fit other categories. The document length is 5653 characters, which is sufficient for a full announcement rather than a brief report publication notice. Confidence is high due to clear content type and absence of financial or regulatory report elements.
2006-12-13 English
2006 Form 20-F filed with US SEC 131 pages ?Kb
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the United States Securities and Exchange Commission (SEC) for the fiscal year ended June 30, 2006. Form 20-F is an annual report filed by foreign private issuers and is equivalent to the annual report (10-K) filed by U.S. domestic companies. The document contains detailed financial data, operating and financial review, information on directors and senior management, major shareholders, financial statements, and exhibits. The length of the document (15,000 characters) and the presence of comprehensive financial and operational information confirm it is the full annual report itself, not just an announcement or certification. Therefore, the correct classification is Annual Report (10-K).
2006-12-06 English
Appendix 3B 9 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically ordinary shares issued upon exercise of options under an employee option plan. It includes details such as the number and class of securities issued, issue price, purpose of the issue, and dates related to the securities. The document references ASX rules and is structured as a formal notification to the stock exchange about a capital change event. There is no financial performance data, management discussion, or audit information. The content aligns with announcements about new share issues or capital changes rather than a full report or earnings release. Therefore, the document fits the category of a Share Issue/Capital Change announcement.
2006-12-06 English
Ceasing to be a substantial holder 1 page ?Kb
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' under the Corporations Act 2001, Section 671B, which relates to a 'Notice of ceasing to be a substantial holder.' The content details changes in relevant interests, changes in association, and addresses related to substantial holders. This type of filing is a notification about changes in significant share ownership levels, specifically ceasing to be a substantial holder. It is not a financial report, earnings release, or management information. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is a substantive notification rather than a brief announcement or certification.
2006-11-30 English
Change in substantial holding 6 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is an ASIC Form 604, which is a Notice of change of interests of a substantial holder under the Corporations Act 2001. It details changes in share ownership percentages and voting power of Orbis Global Equity Fund Limited in Pharmaxis Ltd. The document is a regulatory filing notifying the stock exchange and the public of changes in major shareholdings. It is not a financial report, earnings release, or management discussion. It is specifically a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document length is substantial and contains detailed tables of shareholding changes, confirming it is the actual notification, not just an announcement of a report.
2006-11-30 English
Appendix 3B Exercise of employee options 9 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) announcement for new issue of securities, application for quotation of additional securities, and related agreements. It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including number of shares, issue price, and dates. This type of document is a capital/financing update related to share issuance and securities listing, not a full financial report or earnings release. It is not an announcement of a report publication but a direct regulatory filing about capital changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence level.
2006-11-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.